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Abstract
Background: Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study
of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median
progression-free survival of 4.6 months. nab-Paclitaxel-based regimens (with gemcitabine or carboplatin ±
bevacizumab) also demonstrated efficacy and safety in first-line phase II trials of human epidermal growth factor
receptor 2-negative metastatic breast cancer.
Trial design: In this international, multicenter, open-label, randomized phase II/III trial, the efficacy and safety of
first-line nab-paclitaxel with gemcitabine or with carboplatin will be compared with gemcitabine/carboplatin
(control arm) for metastatic triple-negative breast cancer.
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Methods: In the phase II portion, 240 patients with measurable metastatic triple-negative breast cancer and
treatment naive for metastatic disease will be randomized 1:1:1 (stratified by disease-free interval: ≤ 1 versus >
1 year) to nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2, nab-paclitaxel 125 mg/m2 plus carboplatin area
under the curve 2 mg ×min/mL, or gemcitabine 1000 mg/m2 plus carboplatin area under the curve 2 mg ×min/mL,
all given on days 1 and 8 of a 21-day cycle. Investigator-assessed progression-free survival (primary endpoint),
overall response rate, overall survival, and safety will be assessed. A ranking algorithm of five efficacy and safety
parameters will be used to pick the “winner” of the nab-paclitaxel regimens. In the phase III portion, 550 patients
will be randomized 1:1 (stratified by disease-free interval: ≤ 1 versus > 1 year, and prior adjuvant/neoadjuvant
taxane use) to the nab-paclitaxel combination arm selected from the phase II portion or to the control arm.
Patients in phase II will not be part of the phase III population. The phase III primary endpoint is blinded,
independently-assessed progression-free survival; secondary endpoints include blinded, independently assessed
overall response rate, overall survival, disease control rate, duration of response, and safety. Biomarker and
circulating tumor-cell exploratory analyses and quality-of-life assessments will also be performed. A list of
approving ethical bodies was provided in Additional file 1.
Discussion: The tnAcity trial aims to identify a new standard cytotoxic chemotherapy regimen for first-line
treatment of metastatic triple-negative breast cancer.
Trial registration: ClinicalTrials.gov: NCT01881230. Date of registration: 17 June 2013.
Keywords: tnAcity, Triple-negative breast cancer, Metastatic, nab-Paclitaxel, Abraxane, Gemcitabine, Carboplatin,
Pick-the-winner trial design
Background
Triple-negative breast cancer (TNBC) accounts for ap-
proximately 15 % to 20 % of all breast cancers and is as-
sociated with an aggressive clinical course and a poor
prognosis [1–5]. TNBC tumors comprise a very hetero-
geneous group of cancers that are poorly differentiated
and demonstrate high rates of proliferation; patients
with TNBC face early disease recurrence and low overall
survival rates compared with patients with other types of
breast cancers. Furthermore, patients with recurring
and/or metastatic TNBC (mTNBC) are more likely to
develop visceral and brain metastases and generally have
a shorter survival than patients with other breast cancer
subtypes [1, 3, 6].
While TNBC represents a highly diverse group of can-
cers, it can be characterized by a lack of the estrogen re-
ceptor (ER) and progesterone receptor (PR) and by the
absence of overexpression of the human epidermal
growth factor receptor 2 (HER2) [4]. The genetic and
molecular heterogeneity of these tumors, shorter median
time from relapse to death, and lack of currently identi-
fied treatment targets make management of TNBC par-
ticularly challenging [2, 4]. Currently in the United
States, the standard treatment option for patients with
mTNBC outside of clinical trials is cytotoxic chemother-
apy; however, these patients respond better to chemo-
therapy than do patients with breast cancers that are
hormone receptor positive [7]. Adding a taxane to
chemotherapy appears to improve outcomes in patients
with TNBC [2]. In addition, platinum-containing regi-
mens have demonstrated antitumor activity in this pa-
tient population [8, 9]. However, given the lack of
prospective randomized data, no optimal standard-of-
care regimen for patients with mTNBC currently exists.
Treatment strategies for mTNBC are largely based on
the National Comprehensive Cancer Network recom-
mendations and other international guidelines for the
overall population of patients with metastatic breast can-
cer [8, 10–12].
While monotherapy with sequential single-agent
chemotherapy is preferred in most cases of metastatic
breast cancer, the National Comprehensive Cancer Net-
work guidelines also recommend some combination reg-
imens that have been explored in mTNBC [8, 9, 13, 14].
Capecitabine plus docetaxel and gemcitabine plus
solvent-based (sb) paclitaxel treatment has demonstrated
efficacy in patients with mTNBC [13, 14]. Another
small, randomized phase II study in the first-line treat-
ment of 53 patients with mTNBC, combination therapy
with docetaxel plus capecitabine compared with doce-
taxel plus cisplatin suggests that the platinum-taxane-
based regimen may be more effective than the
capecitabine-based regimen based on overall response
rate (ORR), progression-free survival (PFS), and overall
survival (OS) [13].
The rationale for including platinum agents in the
treatment of TNBC is supported by a growing body of
preclinical and clinical evidence, with its basis in ob-
served platinum-conferred sensitivity as a function of
the impaired homologous recombination repair mecha-
nisms present in TNBC and breast cancer characterized
by mutations in the breast cancer susceptibility gene
(BRCA) [15–18]. Increased sensitivity to cisplatin was
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demonstrated in a xenograft model of TNBC with
BRCA1-deficient cells [19]. The recent phase III TNT
trial evaluated carboplatin versus docetaxel treatment in
patients with metastatic or recurrent locally advanced
triple-negative or BRCA1/2 mutated breast cancer [20].
Although results did not support superior activity of car-
boplatin compared with docetaxel in unselected patients
with TNBC, treatment with carboplatin resulted in a
significantly higher ORR versus docetaxel in patients
with BRCA1/2 mutations (68 % versus 33.3 %; P = 0.03).
However, in the multicenter, single-arm phase II
TBCRC009 trial evaluating single-agent platinum agents
in mTNBC, 6 patients (7 %) who achieved durable re-
sponses (34–69 months) were long-term survivors and
remained off all therapy; all of these patients had
BRCA1/2 wild type (5) or unknown (1) mutation status
and had received platinum therapy as first-line or
second-line therapy for mTNBC [17].
The TBCRC009 trial also evaluated first-line or
second-line treatment with cisplatin or carboplatin in
patients with mTNBC [17]. Grouped efficacy results in-
cluded an ORR of 26 % and a median PFS of 2.9 months
(n = 86), with a higher ORR in patients receiving first-
line treatment than in those receiving treatment in the
second-line setting (29 % versus 12 %).
Platinum agents in chemotherapy combinations have
demonstrated activity in patients with TNBC both in the
neoadjuvant and metastatic settings [9, 16, 21, 22]. In
the metastatic setting, a randomized phase II study com-
pared the addition of iniparib with gemcitabine plus
carboplatin in patients with TNBC. Gemcitabine plus
carboplatin resulted in a median PFS of 3.6 months and
a median OS of 7.7 months (n = 62) [16]. In a subse-
quent confirmatory randomized phase III study compar-
ing these 2 regimens, gemcitabine plus carboplatin
demonstrated median PFS and OS of, respectively, 4.1
and 11.1 months in the intent-to-treat (ITT) population
and 4.6 and 12.4 months based on an exploratory ana-
lysis in patients receiving first-line treatment [9]. Even
though the phase III trial did not meet its prespecified
criteria for the coprimary endpoints of PFS (P = 0.027)
and OS (P = 0.28), it provided a baseline for sample size
calculation for future randomized trials in mTNBC.
nab-Paclitaxel, an albumin-bound, 130-nm–particle for-
mulation of paclitaxel (Abraxane; Celgene Corporation,
Summit, NJ, USA), has demonstrated antitumor activity
and a favorable safety profile in patients with HER2-
negative metastatic breast cancer, including those with
mTNBC [23–25]. nab-Paclitaxel was developed to im-
prove the efficacy of taxane treatment while reducing the
toxicity typically associated with the solvents used to for-
mulate paclitaxel and docetaxel [26–28]. In a pivotal phase
III trial, nab-paclitaxel demonstrated a significantly higher
ORR, significantly longer time to progression, and signifi-
cantly greater OS in patients with metastatic breast cancer
receiving second-line or higher treatment compared with
sb-paclitaxel [26]. Based on these findings, nab-paclitaxel
was approved by the US Food and Drug Administration in
2005 for the treatment of patients with metastatic breast
cancer after failure of combination chemotherapy for meta-
static disease or relapse within 6 months of adjuvant
chemotherapy. Prior therapy should have included an
anthracycline unless clinically contraindicated [29]. A sub-
sequent phase II trial in patients with metastatic breast can-
cer demonstrated that nab-paclitaxel administered the first
3 of 4 weeks (qw 3/4) was a feasible and effective regimen
[27, 28]. Recently nab-paclitaxel has also demonstrated
efficacy in patients with TNBC in the neoadjuvant treat-
ment setting [30]. In the large phase III GeparSepto trial,
patients with early breast cancer received either weekly
nab-paclitaxel 125 mg/m2 (reduced from 150 mg/m2) or
sb-paclitaxel, each followed by epirubicin and cyclophos-
phamide. Treatment with nab-paclitaxel resulted in a sig-
nificantly higher pathological complete response (pCR) rate
than sb-paclitaxel (38 % versus 29 %; P = 0.001), and this
effect was also seen in the subgroup of patients with
TNBC (n = 275; 48.2 % versus 25.7 %; P < 0.001).
The addition of nab-paclitaxel to platinum-based ther-
apy has been shown to be an active regimen in patients
with mTNBC [25]. A phase II trial of nab-paclitaxel
100 mg/m2 qw 3/4 in combination with carboplatin area
under the curve (AUC) 2 qw 3/4 and bevacizumab
10 mg/kg every 2 weeks (q2w) demonstrated promising
antitumor activity in patients with mTNBC, resulting in
an ORR of 85 %, a median PFS of 9.2 months, and an ac-
ceptable safety profile [25]. A phase II study evaluated the
combination of nab-paclitaxel plus carboplatin as first-line
treatment for mTNBC [31]. Weekly nab-paclitaxel
plus carboplatin has also demonstrated robust antitu-
mor activity and an acceptable tolerability profile in
the setting of advanced non-small cell lung cancer
(NSCLC) [32]. In a phase III trial of patients with
advanced NSCLC, weekly nab-paclitaxel plus carbo-
platin significantly improved the ORR (the primary
endpoint) compared with sb-paclitaxel.
The combination of nab-paclitaxel plus gemcitabine
has been shown to be effective and tolerable in a
phase II trial in patients with previously untreated
metastatic breast cancer (n = 50), including those with
TNBC [23]. Treatment with nab-paclitaxel 125 mg/m2
plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 3-
week cycle resulted in an ORR of 50 % and a median
PFS of 7.9 months. Furthermore, in the subset of pa-
tients with mTNBC (n = 13), the nab-paclitaxel combin-
ation resulted in an ORR of 77 %. In another phase II trial
(N = 30), the addition of bevacizumab 10 mg/kg q2w to
nab-paclitaxel 150 mg/m2 plus gemcitabine 1500 mg/m2
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resulted in an ORR of 75.9 % and a median PFS of
10.4 months in patients with metastatic breast cancer
[24]. As in the aforementioned trial, this nab-paclitaxel–
based combination in patients with TNBC (n = 13) dem-
onstrated similar activity, with an ORR of 69 %. More re-
cently, the combination of nab-paclitaxel and gemcitabine
has been approved and is now standard therapy for pa-
tients with metastatic pancreatic cancer based on a ran-
domized phase III trial of nab-paclitaxel and gemcitabine
versus gemcitabine (MPACT). The study demonstrated a
significant improvement in overall survival, response rate,
and PFS, and the combination was well-tolerated [33, 34].
Taken together, these findings support further evaluation
of this combination in the mTNBC setting.
Here, we present the study design of the phase II/III
tnAcity (Triple-Negative Albumin-bound paclitaxel
Combination International Treatment Study) trial, which
will evaluate the efficacy and safety of two nab-paclitaxel
combination regimens (with either gemcitabine or car-
boplatin) compared with that of gemcitabine plus carbo-
platin as treatment for mTNBC. The dosages and
schedule of administration of gemcitabine and carbopla-
tin were adjusted to be the same across treatment arms.
Methods/Design
Overall study design
tnAcity is an international, multicenter, open-label, ran-
domized phase II/III trial designed to test weekly nab-
paclitaxel in combination with gemcitabine or carbopla-
tin, compared with gemcitabine plus carboplatin, as
first-line treatment for patients with mTNBC. Patients
will be enrolled at approximately 150 sites globally. The
aim of the randomized phase II portion of the study is
to assess the safety and efficacy of nab-paclitaxel plus
carboplatin and nab-paclitaxel plus gemcitabine in a
homogeneous mTNBC patient population. A defined
ranking algorithm will then determine the selection of
one of these nab-paclitaxel–based regimens as the ex-
perimental arm to be compared with gemcitabine plus
carboplatin in the phase III portion of the study (Fig. 1).
Participants
A total of 790 women (approximately 240 patients in the
phase II portion and 550 patients in the phase III por-
tion) who are at least 18 years old with measurable
mTNBC (ER negative, PR negative, and lacking HER2
overexpression) will be enrolled in this study. No prior
cytotoxic chemotherapy for metastatic disease is allowed,
but patients may have received prior adjuvant or neoad-
juvant therapy. Patients must have previously received
adjuvant or neoadjuvant anthracycline therapy, unless
not indicated by the treating physician. Patients in the
phase II portion of the study will not be part of the
phase III population. Table 1 summarizes the major eli-
gibility criteria.
Ethical considerations and approvals
This study is being conducted with Good Clinical Prac-
tice as described in the International Conference on
Harmonization Guideline E6 and in accordance with
general ethical principles outlined in the Declaration of
Helsinki. All relevant ethical approvals from institutional
review board/independent ethics committee have been
obtained prior to commencement (see Additional file 1
for details). Investigators will act in accordance with ap-
plicable national and local laws of pertinent regulatory
authorities. The trial is registered at ClinicalTrials.gov
(NCT01881230).
Consent
Consent must be obtained by the investigator prior to
any study-related procedures. If a protocol is amended
and it impacts the content of the informed consent, the
consent document must be revised.
Therapy response assessment
Response will be assessed by Response Evaluation Cri-
teria In Solid Tumors (RECIST) 1.1 guidelines on images
obtained with computed tomography scans. Scans will
be performed at screening and every 6 weeks (±5 days)
from randomization. Safety will be evaluated according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) Version 4.0.
Intervention and outcomes
Phase II portion of the study
The primary objective of the open-label phase II portion
of this trial is to evaluate the efficacy and risk/benefit pro-
files of the two nab-paclitaxel experimental treatments in
order to identify the nab-paclitaxel combination that will
be used in the phase III portion of the study (selection
algorithm discussed later). Approximately 240 patients
with mTNBC and no prior chemotherapy for metastatic
disease (n = 80 per arm) will be randomized 1:1:1, strati-
fied by disease-free interval (DFI; ≤ 1 year versus > 1 year),
to 2 nab-paclitaxel combination arms and 1 comparator
arm: arm A (nab-paclitaxel 125 mg/m2 plus gemcitabine
1000 mg/m2), arm B (nab-paclitaxel 125 mg/m2 plus car-
boplatin AUC 2 mg ×min/mL), and arm C (gemcitabine
1000 mg/m2 plus carboplatin AUC 2 mg ×min/mL) given
intravenously (IV) on days 1 and 8 of a 21-day cycle. En-
rollment will continue until at least 240 patients have been
randomized or the phase III investigational arm has been
selected. The primary endpoint of investigator-assessed
PFS will be evaluated based on RECIST 1.1 guidelines.
Secondary endpoints include investigator-assessed ORR
according to RECIST 1.1 guidelines, percentage of
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patients who initiate cycle 6 while receiving doublet
chemotherapy, OS, and safety. This portion of the trial will
also explore time to second-line therapy or death. Add-
itional exploratory endpoints include enumeration of cir-
culating tumor cells as a surrogate marker for efficacy,
and correlative studies. Since the contributions of each
drug to each doublet can, in principle, be deconvolved by
comparison with the other arms, the design of the phase
II portion presents certain opportunities for testing of
putative predictive markers and for predictive marker dis-
covery. Correlative sampling includes archival tumor tis-
sue, which will be analyzed for molecular profiles,
including protein, tumor cell mutations and gene
expression. Plasma samples are also being obtained at
baseline and cycle 3 in order to characterize tumor-
derived cell-free DNA using digital polymerase chain reac-
tion or whole-exome sequencing. Secreted protein acidic
and rich in cysteine (SPARC) has been hypothesized to be
a potential predictive biomarker for nab-paclitaxel effi-
cacy, and higher SPARC expression has been reported in
TNBC [35–37]. However, clinical data associating SPARC
status with treatment efficacy in breast cancer are equivo-
cal [35, 36, 38, 39]. Analysis of SPARC is not currently pri-
oritized in the phase II portion of the trial.
Identification of the nab-paclitaxel experimental arm
for use in the phase III portion of the trial will be based
Fig. 1 Overall study design. AUC, area under the curve; Carbo, carboplatin; d, day; DFI, disease-free interval; Gem, gemcitabine; nab-P, nab-
paclitaxel; q3w, every 3 weeks
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on an algorithm ranking the performance of five key effi-
cacy and safety endpoint parameters preselected by the
steering committee as well as the total phase II efficacy
and safety data (Table 2). The 5 parameters include the
hazard ratio (HR) of PFS (nab-paclitaxel plus gemcita-
bine/nab-Paclitaxel plus carboplatin), ratio of ORR, per-
centage of patients who initiated cycle 6 while receiving
doublet combination therapy, percentage of patients
who discontinued all study treatment due to adverse
events (AEs), and percentage of patients with
myelosuppression-related events. The nab-paclitaxel ex-
perimental arms from the phase II portion of the trial
will be ranked by endpoint, and the nab-paclitaxel regi-
men with the more desirable treatment effect with re-
spect to the evaluated endpoint will receive the higher
rank. The nab-paclitaxel regimen with the highest total
rank in the five endpoint parameters will be selected as
the experimental arm in the phase III portion of the trial
if the totality of the data supports the conclusion. The
PFS and ORR efficacy endpoints each carry twice the
weight of the remaining three endpoints. A nab-pacli-
taxel experimental arm should demonstrate greater effi-
cacy in both PFS and ORR or in either PFS or ORR and
at least two of the three remaining efficacy and/or safety
endpoint parameters in order to be identified as the ex-
perimental arm for the phase III portion of the trial.
This ranking algorithm will be used when approximately
144 total PFS events from 3 arms have been observed.
The gemcitabine plus carboplatin regimen in the phase
II portion of the study will not be ranked but will rather
serve as a reference for descriptive comparisons between
the two nab-paclitaxel experimental arms.
Phase III portion of the study
The primary objective of the phase III portion of this trial
is to compare the PFS of patients receiving the selected
nab-paclitaxel regimen from the phase II portion of the
trial (nab-paclitaxel plus either gemcitabine or carbopla-
tin) with that of patients receiving gemcitabine plus carbo-
platin, as assessed by independent radiologist(s) blinded to
Table 2 Five parameters for selection of the nab-paclitaxel
regimen for phase III evaluation
Efficacy and safety endpoint parameters
HR of PFS (nab-P + Gem/nab-P + Carbo)a
Ratio of ORRa
Percentage of patients who initiated cycle 6 while receiving doublet
combination therapy
Percentage of patients with myelosuppression-related eventsb
Percentage of patients who discontinued all study treatment due to AEs
= Rank sum
aCarries twice the weight of the remaining three endpoints
bPercentage of patients with myelosuppression-related events is the percentage
of patients with any of the following events: grade 3/4 neutropenia, grade 3/4
thrombocytopenia, grade 3/4 anemia, febrile neutropenia AEs, grade 3/4 bleeding
AEs, red blood cell transfusion, or platelet transfusion. Each patient will be
counted only once in the total percentage
AE adverse event, Carbo carboplatin, Gem gemcitabine, HR hazard ratio, nab-P
nab-paclitaxel, ORR overall response rate, PFS progression-free survival
Table 1 Eligibility criteria for the Triple-Negative Albumin-bound paclitaxel Combination International Treatment Study (tnAcity) trial
Key inclusion criteria Key exclusion criteria
Female, aged≥ 18 years Concurrent chemotherapy or any other antitumor breast cancer
therapy
Measurable metastatic disease
Pathologically confirmed as triple negative, defined as ER and PR expression
both < 1 % of tumor cell nuclei per ASCO/CAP guidelinesa and HER2
negative per ASCO/CAP guidelinesa (IHC 0 or
1+ or FISH−, or IHC 2+ and FISH−)
Concurrent chemotherapy or any other antitumor therapy for
breast cancer. Prior immunotherapy or monoclonal antibody
therapy for metastatic breast cancer is acceptable
If prior ER/PR/HER2+ breast cancer history, must have pathologically
confirmed TN disease in≥ 1 metastatic site
Receipt of prior cytotoxic chemotherapy after incomplete resection of
locoregional recurrent disease
ECOG PS 0–1
History or current evidence of brain metastasis, including
leptomeningeal involvement
No prior cytotoxic chemotherapy for metastatic disease; prior
radiation therapy allowed
History of other primary malignancy in the past 5 years, except
prior history of breast or in situ/basal/localized squamous cell skin
cancerMust have received previous adjuvant or neoadjuvant anthracycline
therapy unless not indicated by physician Baseline peripheral neuropathy grade≥ 2 by NCI CTCAE v4.0
Patients with newly diagnosed mTNBC are eligible if anthracycline
not indicated by physician
Patients with bone as the only site of metastatic disease
Completion of prior neoadjuvant or adjuvant chemotherapy
≥ 6 months before randomization or≥ 12 months if containing
taxane, gemcitabine, or platinum agents
Patients with regional lymph node as the only site of metastatic
disease
aLocal pathology review will be conducted following ASCO CAP guidelines (2013 preferred, 2007 acceptable)
ASCO, American Society of Clinical Oncology, CAP College of American Pathologists, ECOG PS Eastern Cooperative Oncology Group performance status, ER
estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, mTNBC metastatic
triple-negative breast cancer, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, PR progesterone receptor, TN triple-negative,
TNBC triple-negative breast cancer
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treatment assignment using RECIST 1.1 guidelines. This
portion will be an active comparator–controlled, random-
ized, multicenter, open-label study designed to compare
treatment arm 1 (nab-paclitaxel combination treatment
arm selected from the phase II portion of the study) with
treatment arm 2 (gemcitabine 1000 mg/m2 plus carbopla-
tin AUC 2 mg ×min/mL), both administered IV on days 1
and 8 of a 21-day cycle. Approximately 550 patients will
be randomized 1:1 (n = 275 patients per arm), stratified by
DFI (≤1 year versus > 1 year) and prior adjuvant or neoad-
juvant taxane treatment (yes or no), into the phase III por-
tion of this study. The ORR, OS, investigator-assessed
PFS, disease control rate, duration of response, and safety
will also be evaluated. In addition, time to second-line
therapy or death, healthcare resource utilization, quality of
life, and analysis of tumor samples (based on phase II ob-
servations) in patients who agree to participate will be
explored.
Treatment duration and modifications
Treatment in both the phase II and III portions will con-
tinue until progressive disease or unacceptable toxicity.
In the event of a hypersensitivity reaction or a clear tox-
icity to one of the treatment components, the investiga-
tor will permanently discontinue the suspect agent and
continue monotherapy treatment with the remaining
agent. If the toxicity is believed to be caused by both
treatment components, both components will be modi-
fied or discontinued.
Follow-up
All patients will be monitored for new or existing AEs
for 28 days after treatment discontinuation using the
NCI CTCAE Version 4.0. Follow-up will include phys-
ical examination and weight; vital signs; concomitant
medication evaluation, including opioid analgesic con-
sumption and new anticancer treatment; concomitant
procedure evaluation; Eastern Cooperative Oncology
Group performance status; AE evaluation; complete
blood count with differential, including red blood cell
count, hemoglobin, hematocrit, white blood cell count,
absolute neutrophil count, and platelet count; and a
chemistry panel.
Follow-up for survival will be monitored every 3 months
after treatment discontinuation until a patient dies or the
study closes. Information regarding the start of new anti-
cancer treatment(s) and subsequent disease progression
will be collected. This evaluation may be conducted by
record review and/or telephone contact with the patient’s
treating physician.
Sample size and statistical methods
A sample size of 80 patients per arm was selected for
the phase II portion of the study to permit qualitative
comparisons of toxicity between the 2 nab-paclitaxel
arms and to provide preliminary data on antitumor ac-
tivity. This should also provide an approximate 80 %
marginal power with a 2-sided significance level of 0.2 to
differentiate an experimental regimen and the control
arm, assuming a median PFS of 7.1 months for patients
in the experimental arm and 4.6 months for those in the
control arm. Exploratory pairwise comparisons will test
the effect of nab-paclitaxel when 96 PFS events have
been observed from 160 patients.
The phase III portion of the study is designed to enroll
550 patients (330 PFS events), which provides an ap-
proximate 90 % power to detect an HR of 0.70 for PFS
with a 2-sided 5 % significance level. Assuming a median
PFS of 4.6 months for the gemcitabine plus carboplatin
arm, this represents a 43 % improvement in median PFS
for the nab-paclitaxel arm.
Randomization
Central randomization via a permuted-block design and
an interactive voice response system will be imple-
mented for both the phase II and III portions of the
study.
Data management and analysis
A data monitoring committee (DMC) will be established
to review patient disposition, demographics, cancer his-
tory and baseline lesion status, AEs by grade classifica-
tion, and myelosuppression by grade classification. For
the phase II portion of the study, the DMC will review
ongoing safety and dosing data when 20 patients are
randomized per arm (total of 60 patients) and also when
the last randomized patient from this initial group fin-
ishes the first treatment cycle. When approximately 100
PFS events are observed in the phase III portion of the
study, the DMC may recommend stopping the study
early for futility if the conditional power is ≤ 5 %.
Study population definitions
The primary efficacy analysis will be performed on the
intent-to-treat population, which includes all randomized
patients regardless of whether they received any investiga-
tional product (IP) or had any efficacy assessments col-
lected. Confirmatory efficacy analysis will be performed
on the efficacy-evaluable population, which includes all
randomized patients who meet the eligibility criteria, re-
ceive at least one dose of assigned IP, and have at least one
baseline and post-baseline efficacy assessment(s). Safety
and tolerability analyses will be performed on the treated
population, which includes all randomized patients who
receive at least one dose of IP.
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Discussion
An optimal treatment for TNBC has not yet been identi-
fied. A lack of a validated target for development of
molecular-oriented therapy and the poor prognosis of
patients with advanced-stage disease make TNBC a
significant challenge for both patients and oncologists
[2, 3]. Higher response rates observed with combination
chemotherapy regimens may support the role of such
treatments for the management of mTNBC [8]. In
patients with TNBC, relapses occur frequently following
a short DFI and ARE accompanied by a high tumor bur-
den coupled by symptomatic visceral involvement [1].
Whether this short DFI is indicative of primary che-
moresistance remains to be determined. With respect to
high tumor burden and symptomatic visceral involve-
ment, rapid disease control is of paramount importance
and may be best achieved with combination chemother-
apy. However, combination treatments for patients with
TNBC are difficult to explore in a landscape with no
well-defined standard of care for comparison. The tnA-
city trial will further current understanding by poten-
tially identifying a suitable first-line chemotherapeutic
combination regimen for use in future clinical trials, in-
cluding those with targeted agents.
Chemotherapy currently remains the best systemic
treatment strategy for patients with TNBC. Various
molecular subtypes of TNBC have been identified [40],
although at this time there is no single molecular alter-
ation common to all TNBC tumors. Given this disease
heterogeneity and the lack of a shared targetable muta-
tion for drug therapy development, chemotherapy con-
tinues to be the foundation of effective treatment
options, with a broad application that addresses the pro-
found chemosensitivity of these tumors. Furthermore,
some trials of targeted agents are restricted to specific
aberrations and often address only a subset of patients
[9, 16]. This appears to be true in the adjuvant setting as
well, since the addition of bevacizumab to early-stage
adjuvant chemotherapy did not improve outcomes [41].
In the metastatic disease setting, the poly ADP ribose
polymerase–like agent iniparib added to a backbone of
gemcitabine plus carboplatin did not significantly improve
disease-free survival in a large phase III trial of patients
with TNBC [9]. The importance of establishing an effective
chemotherapy regimen for patients with TNBC is further
emphasized by trials with targeted agents, since chemo-
therapy can serve as a backbone for testing these agents in
selected patients with corresponding mutations. A recent
meta-analysis of 12 trials comprising 2054 patients with
TNBC found that, when coupled with conventional
chemotherapy, targeted therapy demonstrated gains in the
PFS of these patients [42]. Combining cytotoxic agents
such as sb-paclitaxel, docetaxel, capecitabine, anthracy-
clines, gemcitabine, and vinorelbine with the targeted agent
bevacizumab resulted in a superior PFS when compared
with chemotherapy alone. Similar results for PFS were re-
ported for treatment with gemcitabine or capecitabine plus
sorafenib versus chemotherapy alone in the second-line
setting.
The tnAcity trial will use a ranking algorithm based
on predefined efficacy and safety parameters to
systematically select the most clinically beneficial
nab-paclitaxel–based regimen from the phase II
portion of the study for comparison with the control arm
in the phase III portion (Table 2). In this algorithm, the
PFS and ORR endpoints carry twice the weight of the
remaining three endpoints to reflect the importance of ef-
ficacy in this evaluation. The pick-the-winner algorithm
balances the importance of efficacy with the need to
minimize toxicities, especially those that limit the ability
to deliver active therapy. The nab-paclitaxel combination
doses and schedules evaluated in this study were chosen
carefully based on the experience with nab-paclitaxel/
gemcitabine in pancreatic cancer and nab-paclitaxel/
carboplatin in NSCLC, while matching the doses and
schedule of the gemcitabine/carboplatin regimen
evaluated in the TNBC phase II and III trials of
iniparib and commonly used in patients with TNBC
[9, 16, 32, 33, 37, 43]. When compared with the dose
used to treat pancreatic cancer, nab-paclitaxel/gemci-
tabine dose intensity was reduced in the tnAcity trial to
decrease associated neurotoxicity and myelosuppres-
sion. The nab-paclitaxel/carboplatin treatment regimen
was also slightly modified compared with the schedule
for NSCLC, with the introduction of a 1-week treatment
break to reduce treatment-related AEs. Of note, the
recently fully recruited neoadjuvant ADAPT trial (West
German Study Group) has used the same 2 nab-paclitaxel
chemotherapy combinations as the phase II part of tnAcity
for 12 weeks before surgery [44]. Final pCR results are ex-
pected for the end of 2015 and may substantiate the results
of the ranking algorithm.
The tnAcity trial will enable robust treatment analysis
of a prospectively defined patient population in mTNBC.
The trial results may identify a nab-paclitaxel–based
cytotoxic chemotherapy combination as a new first-line
standard treatment regimen for mTNBC. Additionally,
biomarker analyses may advance current understanding
of TNBC biology and response to treatment.
Trial status
The trial is currently enrolling patients.
Additional file
Additional file 1: Approving ethical bodies. This file lists name,
type, and location of ethical bodies that approved this study.
(XLSX 22 kb)
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